Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × ER+ Breast Cancer × Tamoxifen × Clear all

Phase

Phase 4 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 88 Carcinoma, Intraductal, Noninfiltrating 11 Breast Carcinoma In Situ 9 Ovarian Neoplasms 6 Neoplasm Metastasis 6 Breast Neoplasms, Male 6 Neoplasms 5 Glioblastoma 4 Central Nervous System Neoplasms 4 Inflammatory Breast Neoplasms 3 Gliosarcoma 3 Urinary Bladder Neoplasms 2 Prostatic Neoplasms 2 Pancreatic Neoplasms 2 Glioma 2 Fallopian Tube Neoplasms 2 Breast Cancer Female 2 Brain Neoplasms 2 Astrocytoma 2 Uveal Melanoma 1 Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Risk Reduction Behavior 1 Recurrence 1 Premenopausal Breast Cancer 1 Oligodendroglioma 1 Non Metastatic Breast Cancer 1 Newly Diagnosed Hormone Positive Clinical Stage 1 or 2 Breast Cancer 1 Neuroendocrine Tumors 1 Multiple Endocrine Neoplasia Type 1 1

Interventions

palbociclib 1 exemestane 1 elacestrant 1 Tamoxifen 1 Letrozole 1 Fulvestrant 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04985266 2024-12-05

TRAK-ER

Royal Marsden NHS Foundation Trust

Phase 2 Recruiting

ER+ Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡